PBX3 as a biomarker for the early diagnosis and prediction of prognosis of glioma

Cuicui Pan ¹, Xueli Bai ¹, Na Li ²

⁰Department of Clinical Laboratory, Shandong Provincial Hospital Affiliated to Shandong First Medical University, Jinan, China.

Plos One +

|

February 7, 2024

View abstract on PubMed

Summary

PBX3 is highly expressed in gliomas and predicts poor prognosis in low-grade glioma (LGG) patients. This transcription factor may be a valuable biomarker for early diagnosis and predicting outcomes in glioma.

Area Of Science

Oncology
Molecular Biology
Genetics

Background

PBX3 (Pre-B-cell leukemia transcription factor 3) is implicated in cancer development.
Its role in gliomas, particularly low-grade gliomas (LGG) and glioblastoma (GBM), is not well understood.
Understanding PBX3's function in gliomas is crucial for developing targeted therapies.

Purpose Of The Study

To investigate the expression of PBX3 in glioma tissues.
To analyze the correlation between PBX3 expression and clinical features, including patient survival.
To explore the potential of PBX3 as a prognostic biomarker for glioma.

Main Methods

Utilized TCGA, GEPIA, CGGA, and CCLE databases for expression analysis.
Performed univariate and multivariate Cox regression analyses for survival outcomes.
Employed Gene Set Enrichment Analysis (GSEA) and co-expression analysis to explore PBX3 function.

Main Results

PBX3 expression is elevated in gliomas and correlates with higher malignancy.
High PBX3 expression is an independent predictor of poor overall survival (OS) and progression-free survival (PFI) in LGG patients.
PBX3 demonstrates potential as a diagnostic and prognostic biomarker for LGG.

Conclusions

PBX3 plays a significant role in glioma development and progression.
PBX3 expression levels can aid in predicting glioma patient prognosis.
Further research into PBX3's mechanisms in glioma is warranted.